What is Tyra Biosciences, Inc.'s earnings per share (EPS)?

Tyra Biosciences, Inc. (TYRA) reported diluted earnings per share of $-2.01 for fiscal year 2025. This represents a -33.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Tyra Biosciences, Inc. Financials

TYRA

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Tyra Biosciences, Inc. (TYRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TYRA FY2025 2026-05-13

Tyra’s economics are dominated by research spending, while an asset-light balance sheet keeps burn tied to science rather than factories.

In FY2025, free cash flow of -$95.3M was almost the same as operating cash flow of -$95.1M because capex was only $141K, so the company’s cash use came from funding research rather than building physical capacity. Cash ended at $77.4M, but that balance was cushioned by $72.5M of investing inflow and $8.1M of financing, which makes the year-end cash figure look steadier than the operating burn alone would suggest.

The expense mix still looks like a development-stage model: FY2025 R&D spending was $102.9M versus SG&A of $29.8M, and R&D represented about 77.5% of operating loss. That means most of the deficit is tied to advancing the pipeline, not supporting a large commercial or corporate structure.

The funding posture has been equity-led rather than debt-led: shares outstanding rose from 43.0M in FY2023 to 53.7M in FY2025 while long-term debt remained absent, and FY2025 liabilities were only $23.4M against equity of $259.2M. The business is preserving balance-sheet flexibility, but it has been financing itself mainly by issuing stock instead of taking on repayment obligations.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Tyra Biosciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Tyra Biosciences, Inc. carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 14.67, Tyra Biosciences, Inc. holds $14.67 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Tyra Biosciences, Inc. generates a -46.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -25.2% the prior year.

Piotroski F-Score Weak

1/9

Tyra Biosciences, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.79x

For every $1 of reported earnings, Tyra Biosciences, Inc. generates $0.79 in operating cash flow (-$95.1M OCF vs -$119.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$132.2M

YoY-27.6%

Tyra Biosciences, Inc.'s EBITDA was -$132.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.6% from the prior year.

Net Income

-$119.9M

YoY-38.7%

Tyra Biosciences, Inc. reported -$119.9M in net income in fiscal year 2025. This represents a decrease of 38.7% from the prior year.

EPS (Diluted)

$-2.01

YoY-33.1%

Tyra Biosciences, Inc. earned $-2.01 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$95.3M

YoY-35.3%

Tyra Biosciences, Inc. generated -$95.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 35.3% from the prior year.

Cash & Debt

$77.4M

YoY-15.9%

5Y CAGR+38.4%

Tyra Biosciences, Inc. held $77.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

54M

YoY+5.8%

Tyra Biosciences, Inc. had 54M shares outstanding in fiscal year 2025. This represents an increase of 5.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-46.3%

YoY-21.1pp

Tyra Biosciences, Inc.'s ROE was -46.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 21.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$102.9M

YoY+28.5%

5Y CAGR+70.2%

Tyra Biosciences, Inc. invested $102.9M in research and development in fiscal year 2025. This represents an increase of 28.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$141K

YoY-78.8%

5Y CAGR-14.7%

Tyra Biosciences, Inc. invested $141K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 78.8% from the prior year.

TYRA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$102.9M+28.5%	$80.1M+28.1%	$62.5M+45.4%	$43.0M+108.4%	$20.6M+186.5%	$7.2M
SG&A Expenses	$29.8M+23.8%	$24.1M+38.3%	$17.4M+9.5%	$15.9M+181.7%	$5.7M+169.9%	$2.1M
Operating Income	-$132.8M-27.4%	-$104.2M-30.3%	-$79.9M-35.7%	-$58.9M-124.2%	-$26.3M-182.8%	-$9.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0-100.0%	$2K+100.0%	$1K0.0%	$1K
Net Income	-$119.9M-38.7%	-$86.5M-25.1%	-$69.1M-25.0%	-$55.3M-110.4%	-$26.3M-181.6%	-$9.3M
EPS (Diluted)	$-2.01-33.1%	$-1.51+6.8%	$-1.62-22.7%	$-1.32+30.9%	$-1.91	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.5M	N/A	$25.5M+4.8%	$24.3M-2.6%	$25.0M	N/A	$22.7M+26.1%	$18.0M
SG&A Expenses	$8.5M	N/A	$7.5M+4.6%	$7.1M+3.7%	$6.9M	N/A	$5.9M+6.7%	$5.5M
Operating Income	-$42.0M	N/A	-$32.9M-4.7%	-$31.5M+1.2%	-$31.9M	N/A	-$28.6M-21.6%	-$23.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$39.3M	N/A	-$29.9M-6.3%	-$28.1M+0.2%	-$28.1M	N/A	-$24.0M-28.4%	-$18.7M
EPS (Diluted)	$-0.64	N/A	$-0.50-6.4%	$-0.470.0%	$-0.47	N/A	$-0.41-28.1%	$-0.32

TYRA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$282.6M-22.3%	$363.6M+61.0%	$225.9M-15.1%	$266.2M-13.2%	$306.7M+1815.6%	$16.0M
Current Assets	$265.4M-23.6%	$347.5M+64.2%	$211.7M-17.7%	$257.3M-15.4%	$304.1M+1889.8%	$15.3M
Cash & Equivalents	$77.4M-15.9%	$92.0M+58.5%	$58.0M-76.9%	$251.2M-16.9%	$302.2M+1884.9%	$15.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.4M+14.8%	$20.4M-5.5%	$21.6M+158.6%	$8.4M+68.3%	$5.0M-83.3%	$29.6M
Current Liabilities	$18.1M+24.0%	$14.6M-4.8%	$15.3M+169.0%	$5.7M+57.7%	$3.6M+94.6%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$259.2M-24.5%	$343.2M+68.0%	$204.3M-20.8%	$257.8M-14.6%	$301.7M+2312.5%	-$13.6M
Retained Earnings	-$371.3M-47.7%	-$251.3M-52.5%	-$164.8M-72.2%	-$95.7M-137.0%	-$40.4M-186.8%	-$14.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$412.0M+45.8%	$282.6M-6.4%	$301.9M-6.1%	$321.5M-6.4%	$343.5M-5.5%	$363.6M-4.5%	$380.6M-3.0%	$392.5M
Current Assets	$394.6M+48.7%	$265.4M-5.6%	$281.2M-6.9%	$302.2M-6.9%	$324.6M-6.6%	$347.5M-5.0%	$365.6M-3.4%	$378.6M
Cash & Equivalents	$85.0M+9.8%	$77.4M+24.9%	$62.0M-37.1%	$98.5M-2.2%	$100.7M+9.5%	$92.0M-11.5%	$103.9M+4.4%	$99.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$24.5M+4.4%	$23.4M+9.8%	$21.3M+10.3%	$19.4M-3.0%	$19.9M-2.3%	$20.4M+11.5%	$18.3M+11.5%	$16.4M
Current Liabilities	$19.3M+6.4%	$18.1M+13.9%	$15.9M+15.3%	$13.8M-3.3%	$14.2M-2.4%	$14.6M+18.0%	$12.4M+19.2%	$10.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$387.6M+49.5%	$259.2M-7.6%	$280.5M-7.2%	$302.1M-6.6%	$323.5M-5.7%	$343.2M-5.3%	$362.3M-3.7%	$376.0M
Retained Earnings	-$410.6M-10.6%	-$371.3M-10.0%	-$337.4M-9.7%	-$307.6M-10.1%	-$279.5M-11.2%	-$251.3M-11.3%	-$225.7M-11.9%	-$201.7M

TYRA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$95.1M-36.4%	-$69.8M-39.2%	-$50.1M+0.3%	-$50.3M-111.8%	-$23.7M-205.9%	-$7.8M
Capital Expenditures	$141K-78.8%	$664K-13.8%	$770K+37.7%	$559K-15.4%	$661K+111.9%	$312K
Free Cash Flow	-$95.3M-35.3%	-$70.4M-38.4%	-$50.9M-0.1%	-$50.8M-108.3%	-$24.4M-202.2%	-$8.1M
Investing Cash Flow	$72.5M+173.6%	-$98.4M+32.0%	-$144.6M-25768.5%	-$559K+13.3%	-$645K-106.7%	-$312K
Financing Cash Flow	$8.1M-96.0%	$202.1M+13051.4%	$1.5M+143.2%	$632K-99.8%	$311.3M+1228.6%	$23.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$32.6M-37.9%	-$23.6M-5.6%	-$22.4M+5.5%	-$23.7M+7.0%	-$25.5M-30.0%	-$19.6M-9.5%	-$17.9M-74.5%	-$10.3M
Capital Expenditures	$88K+54.4%	$57K+46.2%	$39K+25.8%	$31K+121.4%	$14K+133.3%	$6K-88.5%	$52K-88.9%	$470K
Free Cash Flow	-$32.7M-37.9%	-$23.7M-5.6%	-$22.4M+5.4%	-$23.7M+6.9%	-$25.5M-30.0%	-$19.6M-9.2%	-$17.9M-67.3%	-$10.7M
Investing Cash Flow	-$120.2M-449.8%	$34.4M+332.2%	-$14.8M-171.0%	$20.9M-34.8%	$32.0M+360.3%	$7.0M-67.7%	$21.6M+114.9%	-$145.0M
Financing Cash Flow	$160.4M+3324.8%	$4.7M+623.8%	$647K+11.0%	$583K-73.3%	$2.2M+209.8%	$706K-5.0%	$743K+99.2%	$373K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TYRA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-46.3%-21.1pp	-25.2%+8.7pp	-33.9%-12.4pp	-21.5%-12.8pp	-8.7%	N/A
Return on Assets	-42.4%-18.6pp	-23.8%+6.8pp	-30.6%-9.8pp	-20.8%-12.2pp	-8.6%+49.7pp	-58.3%
Current Ratio	14.67-9.1	23.81+10.0	13.80-31.3	45.13-39.0	84.09+75.9	8.22
Debt-to-Equity	0.09+0.0	0.06-0.0	0.11+0.1	0.03+0.0	0.02+2.2	-2.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-10.1%	N/A	-10.7%-1.3pp	-9.3%-0.6pp	-8.7%	N/A	-6.6%-1.7pp	-5.0%
Return on Assets	-9.5%	N/A	-9.9%-1.1pp	-8.7%-0.6pp	-8.2%	N/A	-6.3%-1.5pp	-4.8%
Current Ratio	20.49+5.8	14.67-3.0	17.71-4.2	21.94-0.8	22.78-1.0	23.81-5.7	29.55-6.9	36.46
Debt-to-Equity	0.06-0.0	0.09+0.0	0.08+0.0	0.060.0	0.060.0	0.060.0	0.050.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Bicara Therapeutics BCAX

$1.4B

Rigel Pharmaceuticals Inc RIGL

$556.0M

Anaptysbio Inc ANAB

$1.7B

Palvella Therapeutics Inc PVLA

$1.7B

Septerna, Inc. SEPN

$1.4B

Frequently Asked Questions

Is Tyra Biosciences, Inc. profitable?

No, Tyra Biosciences, Inc. (TYRA) reported a net income of -$119.9M in fiscal year 2025.

What is Tyra Biosciences, Inc.'s EBITDA?

Tyra Biosciences, Inc. (TYRA) had EBITDA of -$132.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Tyra Biosciences, Inc.'s return on equity (ROE)?

Tyra Biosciences, Inc. (TYRA) has a return on equity of -46.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Tyra Biosciences, Inc.'s free cash flow?

Tyra Biosciences, Inc. (TYRA) generated -$95.3M in free cash flow during fiscal year 2025. This represents a -35.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tyra Biosciences, Inc.'s operating cash flow?

Tyra Biosciences, Inc. (TYRA) generated -$95.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Tyra Biosciences, Inc.'s total assets?

Tyra Biosciences, Inc. (TYRA) had $282.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Tyra Biosciences, Inc.'s capital expenditures?

Tyra Biosciences, Inc. (TYRA) invested $141K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Tyra Biosciences, Inc. spend on research and development?

Tyra Biosciences, Inc. (TYRA) invested $102.9M in research and development during fiscal year 2025.

How many shares does Tyra Biosciences, Inc. have outstanding?

Tyra Biosciences, Inc. (TYRA) had 54M shares outstanding as of fiscal year 2025.

What is Tyra Biosciences, Inc.'s current ratio?

Tyra Biosciences, Inc. (TYRA) had a current ratio of 14.67 as of fiscal year 2025, which is generally considered healthy.

What is Tyra Biosciences, Inc.'s debt-to-equity ratio?

Tyra Biosciences, Inc. (TYRA) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tyra Biosciences, Inc.'s return on assets (ROA)?

Tyra Biosciences, Inc. (TYRA) had a return on assets of -42.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Tyra Biosciences, Inc.'s cash runway?

Based on fiscal year 2025 data, Tyra Biosciences, Inc. (TYRA) had $77.4M in cash against an annual operating cash burn of $95.1M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Tyra Biosciences, Inc.'s Piotroski F-Score?

Tyra Biosciences, Inc. (TYRA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tyra Biosciences, Inc.'s earnings high quality?

Tyra Biosciences, Inc. (TYRA) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Tyra Biosciences, Inc.?

Tyra Biosciences, Inc. (TYRA) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.